Woohyung Lee, Minyoung Oh, Jae Seung Kim, Minkyu Sung, Kwangpyo Hong, Bong Jun Kwak, Yejong Park, Eunsung Jun, Ki Byung Song, Dae Wook Hwang, Jae Hoon Lee, Changhoon Yoo, Kyu-Pyo Kim, Inkeun Park, Jae Ho Jeong, Heung-Moon Chang, Baek-Yeol Ryoo, Jung Bok Lee, Song Cheol Kim
BACKGROUND: There is no standardized assessment for evaluating response although neoadjuvant chemotherapy (NAT) is widely accepted for borderline resectable or locally advanced pancreatic cancer (BRPC or LAPC). This study was aimed to evaluate NAT response using positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG-PET/CT) parameters alongside carbohydrate antigen (CA) 19-9 levels. METHODS: Patients who underwent surgery after NAT for BRPC and LAPC between 2017 and 2021 were identified...
April 3, 2024: International Journal of Surgery